CIENCIASMEDICASNEWS

jueves, 5 de noviembre de 2026

Viewpoint: From Medicaid cuts to MAHA-backed anti-vaccine and chemical hysteria, voters reject Republicans’ science-skeptical agenda STAT News | November 5, 2026

https://geneticliteracyproject.org/2026/11/05/viewpoint-from-medicaid-cuts-to-maha-backed-anti-vaccine-and-chemical-hysteria-voters-reject-republicans-science-skeptical-agenda/ Republicans who championed Medicaid cuts and the Make America Healthy Again (MAHA) movement had a rough Election Day. Democrats seized both chambers of Congress, including stunning wins in deep-red Texas, Kansas and South Carolina, after many candidates ran squarely on health care, as STAT’s elections team reports. The results read as a rebuke of the GOP’s health agenda, from the Medicaid cuts in 2025’s One Big Beautiful Bill Act to RFK, Jr.’s MAHA upheaval. Even MAHA allies turned on the party. Jeffrey Tucker, president and founder of the MAHA-aligned Brownstone Institute, said the GOP’s “failure to take its mandate seriously — to give people back their lives and liberties — has led to what looks like yet another populist revolt in a different form.”

Ever wonder why AI can so easily be duped into manufacturing health misinformation? Bioengineer | November 5, 2026

https://geneticliteracyproject.org/2026/11/05/ever-wonder-why-ai-can-so-easily-be-duped-into-manufacturing-health-misinformation/ Generative AI isn’t just one more pipe that health misinformation flows through. It shapes every stage of the problem, from cooking up false claims to catching, correcting and amplifying their fallout. That’s the conclusion of a new review by University of Maryland communication researcher Xiaoli Nan, as Ophelia Keating reports for Bioengineer.

Viewpoint: “Positive eugenics”: Reviving a movement reviled and condemned for a century The Guardian | November 5, 2026

https://geneticliteracyproject.org/2026/11/05/viewpoint-positive-eugenics-reviving-a-movement-reviled-and-condemned-for-a-century/ Subway ads promising parents their “best baby” are a sign that eugenics has returned in a sleek, consumer-friendly form, argues author Jan Grue in an essay for The Guardian. Grue, who has lived with a rare neuromuscular condition since childhood, warns that today’s “liberal eugenics” swaps state coercion for parental choice but keeps many of the old assumptions.

With technical barriers to human embryo editing falling, ethical concerns escalate Rebecca Roberts | November 5, 2026

https://geneticliteracyproject.org/2026/11/05/with-technical-barriers-to-human-embryo-editing-falling-ethical-concerns-escalate/ Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics. In the paper, Cathy Tie, the founder and chief executive officer of the startup Origin Genomics, proposes that recent advances in genome editing technologies and an increase in public support might finally convince regulators to lift restrictions on the controversial field.

Expert Insights on Personalized Care NTRK Fusion–Positive Lung and Thyroid Cancer CME Tuesday, November 17, 2026 | 11:30 am - 12:00 pm ET

https://na.eventscloud.com/website/99701/ Join expert faculty Dr Nabil F. Saba and Dr Jarushka Naidoo for an interactive 30-minute webinar exploring personalized care strategies for patients with NTRK fusion–positive non-small cell lung cancer (NSCLC) and thyroid cancer. Through real-world case studies, the panel will address critical clinical challenges, including navigating diagnostic hurdles, optimizing genomic testing, differentiating NTRK fusions from common drivers, and timing tyrosine kinase inhibitor (TKI) therapy alongside traditional modalities. Faculty will also share actionable guidance on managing treatment-related adverse effects, preserving long-term quality of life, and facilitating equitable access to targeted care through multidisciplinary coordination. Gain practical, evidence-based insights to refine treatment sequencing and incorporate patient-centered goals into shared decision-making.

Reshaping Gastroesophageal Adenocarcinoma Care: Integrating New Anti-HER2 Therapies CME/CNE/CPE/IPCE Monday, November 9, 2026 | 3:30 pm - 4:15 pm ET

https://na.eventscloud.com/website/99132/ Transform your gastroesophageal adenocarcinoma (GEA) practice by joining expert oncologists Elena Elimova, Samuel J. Klempner, and Kohei Shitara for an interactive, 45-minute online discussion. Unpack the latest clinical trial data for novel anti-human epidermal growth factor receptor 2 (HER2) regimens, learn how to integrate new frontline regimens into care for patients with HER2-positive GEA, and gain insight into postprogression strategies. Faculty will also discuss proactive team-based approaches to toxicity management. Register now to elevate your clinical decision-making.